DEFA14A ·Filed Mar 2, 2026
Proxy solicitation materials
Actionable Insight • Neutral
Monitor for shareholder vote outcome and potential stock price movement around the merger approval date. Watch for any activist opposition despite board support.
Final — all horizons settled through T+60d ⚠ clustered
BCAB ▼ -61.67% at T+60d
NEUTRAL call ✗ call lost -61.67% · α vs SPY -70.99% · entry $10.20 → $3.91
T+1d
-9.31%
call -9.31% · α -8.40%
$9.25
settled 8mo ago
T+5d
-7.35%
call -7.35% · α -6.15%
$9.45
settled 8mo ago
T+20d
-24.51%
call -24.51% · α -16.57%
$7.70
settled 7mo ago
T+60d
-61.67%
call -61.67% · α -70.99%
$3.91
settled 5mo ago
Price Chart
Loading chart...
Executive Summary
BioAtla is holding a special shareholder meeting to approve a merger with its wholly-owned subsidiary. The merger agreement was amended to ensure brokers can vote shares held in street name, addressing a prior quorum issue. The board unanimously recommends approval.
Key Facts
- Special meeting scheduled for March 23, 2026 to approve merger with wholly-owned subsidiary BA Merger Sub, Inc.
- Merger agreement amended to keep company's certificate of incorporation unchanged, allowing broker voting on shares held in street name.
- Amendment addresses quorum issue from previous meeting where brokers couldn't vote on non-routine proposals.
- Board unanimously recommends voting FOR both merger and adjournment proposals.
- Approval requires majority of outstanding shares.
Financial Impact
No financial figures provided in filing
Risk Factors
- Failure to achieve quorum or majority approval could delay or derail the merger
- Potential for shareholder dissent despite board recommendation
Market Snapshot
Exchange
Nasdaq
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001539497-26-000813 |
| Document: 0001539497-26-000813-index-headers.html | 0001539497-26-000813 |
| Document: 0001539497-26-000813-index.html | 0001539497-26-000813 |
| Document: 0001539497-26-000813.txt | 0001539497-26-000813 |
6 reports for BCAB
67% Hit rate @ T+20 Went positive at some point 2 of 5 best @ T+60▲ +61.67%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | S-1 | $1.74 | awaiting T+20 | — | $1.71 (+1.44%) |
Oct 19, 2026 6d ago | 8-K | $1.74 | awaiting T+20 | — | $1.71 (+1.44%) |
Aug 28, 2026 8w ago | 8-K | $1.74 $1.74 | · 0.00% | ▲ +0.26% | $1.71 (+1.44%) |
Mar 31, 2026 29w ago | 8-K | $6.75 $4.04 | ▲ +40.15% | ▲ +49.87% | $1.71 (+74.67%) |
Mar 2, 2026 33w ago | DEFA14A | $10.20 $7.70 | ▼ −24.51% | ▼ −16.57% | $1.71 (−83.24%) |
Mar 2, 2026 33w ago | Press Release | $10.20 $7.70 | ▲ +24.51% | ▲ +16.57% | $1.71 (+83.24%) |
Showing 6 of 6
US Market Status
Market Closed — Opens in 1h 11m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers